¤j¸zª½¸zÀù¤Æ¾ÇªvÀøªº®É¾÷©M°Æ§@¥Î
G¸z¤º¬ì §d©y¬Ã §U²z±Ð±Â(102¦~4¤ë)
¤ÆÀø¬OÀù¯g¯f¤Í̬۷í®`©Èªº¤@Ãö¡A¦ý¤SÁôÁôªY¼¢¦Û¤vªº¯fÁÙ¤£¬O¡uµLÃÄ¥iªv¡v¡C¡u¿©±w¤j¸zÀù¬O§_¤@©wn¤ÆÀø¡H¡v¡B¡u¤ÆÀøªº¤£«K©M°Æ§@¥Î¬O§_·|¼vÅT¤é±`¥Í¬¡¡H¡v¬O±wªÌ©M¼~¤ßªº®aÄÝ̱`°Ýªº°ÝÃD¡C¦ÓÀHµÛªvÀøªº¶i¨B¡A¸ó¹Î¶¤¦X§@½«¬°·©|¡A¦³¨Ç°ÝÃD¦³¤F¦@ÃÑ¡A¦³¨Çµª®×¤Ï¦Ó¦]¤H¦Ó²§¡Aº¥¦³Ó¤H¤ÆÂåÀøªºÁͶաC
¤j¸zª½¸zÀù¤ÆÀøªº¨Ï¥Î¥Dn¦³¤TºØ±¡ªp¡G(1)§@¬°Àù¯g¤wÂಾ©ÎµLªk¤â³N®Ú°£ªÌªº¥D¤OªvÀø (2)¤â³N«á¬°©µ½w´_µo¤Î´£¤É¯f¤Í¦s¬¡´Áªº»²§U©Ê¤ÆÀø(adjuvant chemotherapy)¡A¥H¤Î(3)¤â³N«e¬°¼W¥[§¹¥þ¹ø²M²v(R0 resection rate)¡B«O¯d¨zªù¨Ã´î¤Ö´_µo¾÷·|ªº·s»²§U©Ê¤ÆÀø(neo-adjuvant chemotherapy)¡C¹ï²Ä¤G¡B¤T´Áª½¸zÀù(¸~½Fµo¥Í¦b¨zªù¥H¤W12¤½¤À¤º)¡AY¨Å骬ªp³\¥i¡A§¹¾ã¦a±µ¨ü¡u·s»²§U©Ê¤ÆÀø¦X¨Ö¹qÀø„³¤â³N„³»²§U©Ê¤ÆÀø¡v¬O°ê¤º¥~¤½»{³Ì¦³®ÄªºªvÀø¡F¹ï¥i¶}¤M¤Á°£ªº¤j¸zÀù±wªÌ¡AY§½³¡«I¥Ç¸û²`©Î¦³²O¤Úµ²Âಾ¡A³N«á¤´À³±µ¨ü»²§U©Ê¤ÆÀø¡C¬Û¸û©óª½¸z©T©w¦b°©¬ÖµÄ¤¤¡A¤j¸z¥i¦b¸¡µÄ¤¤²¾°Ê¡A¹qÀø¤£©ö©w¦ì¦]¦Ó¨Ã«D±`³WÀøªk¡A¦ýY¤j¸zÀù§½³¡¤w¦Y¥X¸z¹D©T©w¦b¸¡µÄ¡B©Î¦³¤j¶qªº²O¤ÚÂಾ¡AÂå®v·|Ó§O¦Ò¶q¬O§_¦b³N«eµ¹¤©¤ÆÀø¬Æ¦Ü¹qÀø¡A¥ý±N¸~½FÁY¤p¨Ã±±¨î¥i¯à¤wÂಾ¦ý¥¼³Qµo²{ªºÀù²ÓM«á¦A¤â³N¡A¥Øªº¦b¼W¥[¤â³Nªº¦¨¥\²v¡B´î¤Ö¨Öµo¯g©M³N«áªº´_µo¡C
±`¥Îªº¤j¸zª½¸zÀù¤Æ¾ÇªvÀøÃĪ«¥]¬A5-Fluorouracil(5-FU¡A±`·f°t¸»Ä)¡BIrinotecan¡BOxaliplatin¡BCapecitabineµ¥¡A«e¤TªÌ¬°°w¾¯¡ACapecitabine¬°5-FUªº«eÅXÃĪ«¡A¤fªA«á¦bÅ餺Âà´«¬°¦³®Äªº5-FU¡C³o¨ÇÃĪ«±`¨£ªº°Æ§@¥Î¥]¬Aäú¤ß¹Ã¦R¡BG¸z¤£¾A¡B¦å²y°§C¡A¦U§O¨Ï¥Î·|¦Ò¶q¨xµÇ¥\¯à¡F¥t¥~¡AOxaliplatin²Ö¿n¾¯¶q«á¥i¯à¥X²{¤â¸}³Âµ¥ªº¯«¸g¯fª¬¡A¤fªACapecitabine«h¥i¯à¥X²{¤â´x¤Î¸}³k¥Ö½§¬õ¸~¡B²æ¥Ö¡B¯kµhµ¥©Ò¿×ªº¤â¨¬¯g«J¸s (hand-foot syndrome)¡C
±`¥Îªº¼Ð¹vÃĪ«¥]¬ACetuximab (º¸¥²±oµÎ¡A±wªÌ»Ý¥ýÀËÅçK-RAS°ò¦]µL¬ðÅܤ~¾A¦X¦¹ÃÄ)©MBevacizumab (Àù«ä°±)¡A¹ïÂಾ©Ê¤j¸zÀù¡A¦¹¤G¶µÃĪ«°·«O¤w³q¹L¦X¨Ö¤ÆÀø¦b²Ä¤@½u¨Ï¥Î¡CÂå®v·|¿ï¾Ü¹ï¯f±w³Ì¦w¥þ¤è«Kªº¤ÆÀø³B¤è¡A§Y¨Ï¬O½wºCª`®g«¬ªºÃĪ«¡AÁ{§É¤W¤]±`¥H»´«Kªº¡u¥¤²~¡vª`®g¾¹±a¦^®a¤¤¡A¤£¤@©wn¦í°|¡C
Àù¯gªvÀø¬O¤@³õªø´Á§Ü¾Ô¡A·U§¹¾ãªºªvÀø±`·N¨ýµÛ¸û¦h°Æ§@¥Î©M»ÝÀWÁc´NÂå¡C¡uÂå¥Í§r¡A§Ú²{¦b¨«¶iÂå°|³£·|ı±o®`©È¡v¬O³\¦h¸~½F¤º¥~¬ìÂå®v¸g±`Å¥¨ìªº¤ßÁn¡F¥Ñ©ó¨¤ßªº¤£¾A©M®£Äß¡A¦bªvÀø´Á¶¡©MÂå®v¡u°Q»ùÁÙ»ù¡v¡B¥b³~¦Ó¼o¬Æ¦ÜÂà¦V¥Á«UÀøªkªº¤]¤£¦b¤Ö¼Æ¡A¦ý±`ªá¤FÞªP¿ú§ó½ß¤W°·±d¡C¨ä¹ê´«Ó·Qªk¡AÂå¯fÂù¤è·U¾é¸Ñ¥i¯àªº°Æ§@¥Î¡A¸g¥Ñ¨}¦nªº·¾³q¡A·U¯àµ½¥Î¦¹Âù±§Q¤b¡G±o¨ìÀø®Ä¤SÁקK¤£¥i°fªº¶Ë®`¡C
¤j¸zÀùªºªvÀø»P¤éº¥¶i¡AÁo©úªº¯f¤Í¤£§«¿ï¾Ü±z«H¥ôªºÂå®v¡A¤]«H¥ô±z¿ï¾ÜªºÂå®v¡I
¡i¦^ ¥»´Á¥Ø¿ý¡j